Sung Won Song

Director/Board Member at JW (CAYMAN) THERAPEUTICS CO. LTD

43 year

Consumer Services

Health Technology

Profile

Sung Won Song is currently a Director at EpimAb Biotherapeutics, Inc. and a Non-Executive Director at JW (Cayman) Therapeutics Co. Ltd.
Dr. Song has a graduate degree from The Trustees of Columbia University in The City of New York, a doctorate degree from The Ohio State University, and an undergraduate degree from Korea University.

Sung Won Song active positions

Companies	Position	Start
JW (CAYMAN) THERAPEUTICS CO. LTD	Director/Board Member	28/08/2023
EpimAb Biotherapeutics, Inc. EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016.	Director/Board Member	-

All active positions of Sung Won Song

Training of Sung Won Song

The Trustees of Columbia University in The City of New York	Graduate Degree
The Ohio State University	Doctorate Degree
Korea University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Sung Won Song's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
JW (CAYMAN) THERAPEUTICS CO. LTD	Health Technology

Private companies	1
EpimAb Biotherapeutics, Inc. EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016.	Health Technology